Provided by Tiger Fintech (Singapore) Pte. Ltd.

PDS Biotechnology Corporation

1.33
+0.06004.72%
Post-market: 1.29-0.0400-3.01%16:17 EDT
Volume:141.42K
Turnover:183.77K
Market Cap:60.79M
PE:-1.42
High:1.34
Open:1.29
Low:1.26
Close:1.27
Loading ...

PDS Biotechnology Corp : H.c. Wainwright Cuts Target Price to $13 From $21

THOMSON REUTERS
·
27 Mar

PDS Biotechnology Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Mar

PDS Biotechnology FY 2024 GAAP EPS $(1.03) Beats $(1.11) Estimate

Benzinga
·
27 Mar

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

THOMSON REUTERS
·
27 Mar

Press Release: PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Dow Jones
·
27 Mar

PDS Biotechnology Corp expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
25 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts

Insider Monkey
·
23 Mar

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

GlobeNewswire
·
14 Mar

PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Cartesian Therapeutics (RNAC)

TIPRANKS
·
14 Mar

BRIEF-PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer

Reuters
·
13 Mar

PDS Biotechnology Receives FDA Clearance for Versamune MUC1 Trial in Colon Cancer

MT Newswires Live
·
13 Mar

PDS Biotech Announces FDA Clearance of Ind Application for Combination of Versamune® Muc1 and PDS01ADC to Treat Metastatic Colorectal Cancer

THOMSON REUTERS
·
13 Mar

PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
08 Mar

PDS Biotechnology initiates VERSATILE-003 Phase 3 trial of Versamune HPV

TIPRANKS
·
07 Mar

PDS Biotech Initiates Versatile-003 Phase 3 Clinical Trial Evaluating Versamune® Hpv in Hpv16-Positive Head and Neck Cancer

THOMSON REUTERS
·
07 Mar

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

GlobeNewswire
·
07 Mar

PDS Biotechnology Launches Registered Direct Offering; Shares Up

MT Newswires Live
·
28 Feb

PDS Biotechnology prices 7.33M shares at $1.50 in registered direct offering

TIPRANKS
·
27 Feb